Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 199,913 | 458,578 | 178,494 | 166,797 | 212,527 |
| Cost of Goods | 29,719 | 24,531 | 13,626 | 34,360 | 40,857 |
| Gross Profit | 170,194 | 434,047 | 164,868 | 132,437 | 171,670 |
| Operating Expenses | 222,055 | 211,395 | 198,780 | 216,125 | 198,693 |
| Operating Income | -51,142 | 223,183 | -33,286 | -83,328 | -26,166 |
| Interest Expense | 10,847 | 11,279 | 11,152 | 11,049 | 11,533 |
| Other Income | 3,351 | 4,413 | 2,753 | 2,493 | 1,632 |
| Pre-tax Income | -58,638 | 216,317 | -41,685 | -91,884 | -36,067 |
| Income Tax | 313 | 602 | 466 | 341 | 286 |
| Net Income Continuous | -58,951 | 215,715 | -42,151 | -92,225 | -36,353 |
| Net Income | $-58,951 | $215,715 | $-42,151 | $-92,225 | $-36,353 |
| EPS Basic Total Ops | -0.46 | 1.71 | -0.33 | -0.74 | -0.30 |
| EPS Basic Continuous Ops | -0.46 | 1.71 | -0.33 | -0.74 | -0.29 |
| EPS Diluted Total Ops | -0.40 | 1.67 | -0.33 | -0.74 | -0.30 |
| EPS Diluted Continuous Ops | -0.42 | 1.66 | -0.33 | -0.74 | -0.29 |
| EPS Diluted Before Non-Recurring Items | -0.47 | 1.67 | -0.33 | -0.74 | -0.29 |
| EBITDA(a) | $-50,160 | $224,158 | $-32,226 | $-82,291 | $-25,132 |